Shares of ImmuPharma plc (LON:IMM – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 6.06 and traded as low as GBX 4.38. ImmuPharma shares last traded at GBX 4.60, with a volume of 674,319 shares traded.
ImmuPharma Trading Down 2.3%
The company has a market cap of £27.02 million, a PE ratio of -11.70 and a beta of 2.98. The business has a 50 day simple moving average of GBX 4.50 and a two-hundred day simple moving average of GBX 6.01.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. On average, equities research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
